Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.

Shah AD, Shoback D, Lewiecki EM.

Int J Womens Health. 2015 Jun 2;7:565-80. doi: 10.2147/IJWH.S73244. eCollection 2015. Review.

2.

Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis.

Sugiyama T, Torio T, Miyajima T, Kim YT, Oda H.

Front Endocrinol (Lausanne). 2015 Apr 21;6:54. doi: 10.3389/fendo.2015.00054. eCollection 2015. Review. No abstract available.

3.

[Novel strategies for the development of anabolic agents for treatment of osteoporosis].

Saeki M, Egusa H.

Nihon Yakurigaku Zasshi. 2014 Dec;144(6):277-80. Review. Japanese. No abstract available.

PMID:
25492363
4.

[State of the art treatment of progressive or refractory multiple myeloma].

Schmidt-Wolf IG, Straka C, Scheid C, Einsele H, Goldschmidt H, Engelhardt M.

Dtsch Med Wochenschr. 2014 Oct;139(41):2091-5. doi: 10.1055/s-0034-1387268. Epub 2014 Sep 30. Review. German.

PMID:
25268212
5.

Biological agents in management of osteoporosis.

Tella SH, Gallagher JC.

Eur J Clin Pharmacol. 2014 Nov;70(11):1291-301. doi: 10.1007/s00228-014-1735-5. Epub 2014 Sep 11. Review.

PMID:
25204309
6.

Emerging drugs for osteoporosis.

Feurer E, Chapurlat R.

Expert Opin Emerg Drugs. 2014 Sep;19(3):385-95. doi: 10.1517/14728214.2014.936377. Epub 2014 Jul 4. Review.

PMID:
24995794
7.

[Biological therapy for osteoporosis].

Nakamura S, Tanaka S.

Clin Calcium. 2014 Jun;24(6):919-25. doi: CliCa1406919925. Review. Japanese.

PMID:
24870844
8.

Anti-sclerostin antibodies: utility in treatment of osteoporosis.

Clarke BL.

Maturitas. 2014 Jul;78(3):199-204. doi: 10.1016/j.maturitas.2014.04.016. Epub 2014 May 2. Review.

PMID:
24842796
9.

Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases.

Lewiecki EM.

Ther Adv Musculoskelet Dis. 2014 Apr;6(2):48-57. doi: 10.1177/1759720X13510479. Review.

10.

Status of drug development for the prevention and treatment of osteoporosis.

Schwarz P, Jørgensen NR, Abrahamsen B.

Expert Opin Drug Discov. 2014 Mar;9(3):245-53. doi: 10.1517/17460441.2014.884067. Epub 2014 Feb 4. Review.

PMID:
24490672
11.

Management of bone disease in multiple myeloma.

Terpos E, Berenson J, Raje N, Roodman GD.

Expert Rev Hematol. 2014 Feb;7(1):113-25. doi: 10.1586/17474086.2013.874943. Epub 2014 Jan 16. Review.

PMID:
24433088
12.

Sclerostin: therapeutic horizons based upon its actions.

Costa AG, Bilezikian JP.

Curr Osteoporos Rep. 2012 Mar;10(1):64-72. doi: 10.1007/s11914-011-0089-5. Review.

PMID:
22234741
13.

Sclerostin: a novel target for intervention in the treatment of osteoporosis.

Lewiecki EM.

Discov Med. 2011 Oct;12(65):263-73. Review.

14.

New targets for intervention in the treatment of postmenopausal osteoporosis.

Lewiecki EM.

Nat Rev Rheumatol. 2011 Sep 20;7(11):631-8. doi: 10.1038/nrrheum.2011.130. Review.

PMID:
21931340
15.

Osteoporosis: now and the future.

Rachner TD, Khosla S, Hofbauer LC.

Lancet. 2011 Apr 9;377(9773):1276-87. doi: 10.1016/S0140-6736(10)62349-5. Epub 2011 Mar 28. Review.

16.

Osteoporosis in 2010: building bones and (safely) preventing breaks.

Dennison E, Cooper C.

Nat Rev Rheumatol. 2011 Feb;7(2):80-2. doi: 10.1038/nrrheum.2010.227. Review. No abstract available.

PMID:
21289613
17.

Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis.

Lewiecki EM.

Expert Opin Biol Ther. 2011 Jan;11(1):117-27. doi: 10.1517/14712598.2011.540565. Epub 2010 Nov 29. Review.

PMID:
21114421
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk